10% peppermint oil in ethanol repeatedly applied to the forehead and temples,
does it really help with Acute pain relief for tension-type headache?
research showsGrade D with 28 points. An old 41-person crossover study reported pain reduction across 164 headache attacks from 15 minutes, but a prespecified 209-person follow-up failed its first 120-minute primary endpoint, with 37/94 versus 28/95 responders. The small early trial does not establish acute analgesic efficacy.
ads claimClaims that it is a natural analgesic equivalent to acetaminophen overstate a small non-equivalence trial and a failed follow-up primary endpoint.
Useful facts when choosing a product
- The studied formulation was a specific topical solution of 10% peppermint oil in high-concentration ethanol.
- It was not administered into the eyes or mucosa.
- Inhaled aroma and oral peppermint capsules are different interventions.
Chamgap Semantic Classification Code
Permanent code issued
K.peppermint-oil-10-percent.topical-skin.tension-headache-pain.reduce.vehicleFolk and alternative interventions > 10% peppermint oil in ethanol repeatedly applied to the forehead and temples > Topical skin > Acute pain relief for tension-type headache > Reduction claim > Vehicle
Codex retrospectively verified the principal intervention, delivery, population, endpoint, and comparator from the existing reviewed verdict and issued a permanent semantic code. Secondary outcomes on the page are not transferred as separate claims. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | K · Folk or alternative practice |
|---|---|
| Canonical ingredient or intervention | 10% peppermint oil in ethanol repeatedly applied to the forehead and temples |
| Source or part used | Folk or alternative formulation specified in the verdict; unreported source and manufacturing details remain unverified |
| Formulation or processing | 10% peppermint oil in ethanol repeatedly applied to the forehead and temples |
| Route | Topical skin |
| Dose | 10% peppermint oil in ethanol repeatedly applied to the forehead and temples |
| Duration | Single acute attack |
| Population | 41 participants and 164 headache attacks |
| Effect or condition | Acute pain relief for tension-type headache |
| Primary endpoint | Pain intensity from 15 minutes and comparison with acetaminophen |
| Comparator | Vehicle |
| Duplicate-detection key | peppermint-oil-10-percent|topical-skin|41 participants and 164 headache attacks|tension-headache-pain|Single acute attack |
What the research actually shows
A 10% peppermint-oil ethanol solution was repeatedly applied to the forehead and temples and compared with placebo or acetaminophen. Aromatherapy, enteric capsules, and migraine were excluded.
Why this is classified as D (28)
A larger prespecified trial failed its first primary endpoint after a small early positive study, with weak independence and clinical precision, giving D with 28 points.
Counterpoint. The 37/94 versus 28/95 direction does not prove exactly zero benefit, but it did not meet the prespecified threshold.
Rejudgment record. Cross-check applied — Prioritized the larger registered follow-up's failed first 120-minute primary response over the small old crossover signal and treated the hierarchically second endpoint as exploratory
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | RX | Repeatedly refuted in the same indication |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Response at 120 minutes in acute tension-type headache | D | The larger registered trial's first primary endpoint missed its threshold. |
| Analgesic efficacy equivalent to acetaminophen | D | The early trial was not designed to establish equivalence or noninferiority. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Göbel H et al. 1996 | Randomized double-blind repeated-attack crossover trial | 41 participants and 164 headache attacks | Specific funding and manufacturer involvement unverified | Pain intensity from 15 minutes and comparison with acetaminophen | Less pain than placebo, P<.01; no difference from acetaminophen did not establish equivalence | Small early positive trial |
| Euminz tension-type headache phase 4 study | Registered placebo-controlled phase 4 trial | 209 started and 189 in FAS, 94 versus 95 | Sponsored by Cassella-med GmbH | First primary 120-minute VPRS response and second VAS-SPID | 37/94 versus 28/95; failed the prespecified one-sided .025 threshold. Two-sided Fisher P≈.101 is a Codex calculation from counts | Larger confirmatory follow-up |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-07).
Final verification and publication gate: Codex · Evidence date: 2026-09-07 · Corrections: none
Cite this verdict
[Chamgap] Topical 10% Peppermint Oil for Tension Headache—The Larger Follow-Up Missed Its 120-Minute Primary Endpoint — Evidence Grade D·28. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/topical-ten-percent-peppermint-oil-acute-tension-headache/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.